ABUS
Arbutus Biopharma Corp
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology.
Market Cap: 459 Million
Primary Exchange: NASDAQ
Website: http://www.arbutusbio.com/
Shares Outstanding: 168 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.0042162029836545
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 2812 trading days
From: 2014-03-11 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|